Pleural sarcomatoid mesothelioma

Summary

Pleural sarcomatoid mesothelioma (MONDO:0006380) is a disease and 2 clinical trials. Top therapeutic interventions include pembrolizumab. A subtype of malignant pleural mesothelioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pleural sarcomatoid mesothelioma
Mondo ID	MONDO:0006380
EFO	EFO:1000486
NCIT	C45663
UMLS	C1709578
MedGen	354059
GARD	0024388
Anatomy (UBERON)	UBERON:0000977
Is cancer (heuristic)	no

Also known as: pleura sarcomatoid mesothelioma · pleural sarcomatoid mesothelioma · sarcomatoid mesothelioma of pleura

Data availability: 26 cell lines.

Disease family

This is a subtype of malignant pleural mesothelioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesothelial neoplasm › mesothelioma › pleural mesothelioma › malignant pleural mesothelioma › pleural sarcomatoid mesothelioma

Related subtypes (1): pleural epithelioid mesothelioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05647265	PHASE2	RECRUITING	Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
NCT02399371	PHASE2	COMPLETED	Pembrolizumab in Treating Patients With Malignant Mesothelioma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PEMBROLIZUMAB	4	1